Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 2Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Breast 5Other hematologic neoplasm 4Sarcoma 3Gynecologic 3Genitourinary 3Plasma cell 2Thoracic 1Head & Neck 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 2Lymphoma 1

Interventions

Dexamethasone 140Lenalidomide 60Bortezomib 56Calcium Dobesilate 48Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10isatuximab 9Cyclosporine 9pembrolizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × pegfilgrastim × Plasma cell × Clear all
NCT01355705 2018-09-18

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Stanford University

Phase 1/2 Completed
14 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT02488382 2017-10-17

Lonquek for Autologous Stem Cell Mobilization

Sheba Medical Center

Phase 1/2 Unknown
24 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡